Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.

Lucas C Zarling,Philip A Stevenson,Lorinda A Soma,Christen H Martino,Mary-Elizabeth M Percival,Anna B Halpern,Cristina M Ghiuzeli,Pamela S Becker,Vivian G Oehler,Jason P Cooper,Johnnie J Orozco,Paul C Hendrie,Roland B Walter,Elihu H Estey,Ryan D Cassaday

European journal of haematology（2023）

引用 0|浏览14

暂无评分

摘要

Our findings support continued use of Hyper-CVAD for Ph- ALL but suggest that DA-EPOCH may be a reasonable alternative for Ph+ ALL. These data also highlight a potential role for DA-EPOCH in resource-limited settings or when more intense therapy is not feasible.

查看译文

关键词

acute lymphoblastic leukemia, adults, DA-EPOCH, Hyper-CVAD, induction chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要